For over 50 years, psychiatrists focused on dopamine and serotonin pathways for antidepressant treatment. Since the discovery of the antidepressant effects of ketamine roughly 25 years ago, psychiatrists appreciated that depression could also be treated with great efficacy by targeting the glutamate pathway, the main highway for information in the cerebral cortex and a chemical key to learning and memory.
